electroCore announces NICE draft guidance on use of gammaCore
electroCore announced that the National Institute for Health and Care Excellence has published draft guidance on the use of gammaCore, a non-invasive vagus nerve stimulator for preventing and treating cluster headache in adults, which concludes that "evidence supports the case for adopting gammaCore to treat cluster headache in the NHS. gammaCore reduces the frequency and intensity of cluster headache attacks and improves quality of life." In the draft guidance, NICE highlights that the use of gammaCore in addition to standard care therapy could save the NHS GBP 450 per patient in the first year compared to standard care alone. The guidance also states that gammaCore should be used following a three-month trial period where it has shown to be effective in reducing cluster headache symptoms. Additionally, clinical experts suggest that around 25,000 people in the U.K. with cluster headache are likely to respond to treatment with gammaCore. In order to finalize its medical technology guidance documents, NICE will solicit comments from stakeholders on the draft guidance. After the end of this consultation period, the review committee will meet to discuss whether to amend its draft recommendations in view of the consultation comments.